Presolicitation Notice - BARDA Vaccine Medical Countermeasures for Pandemic Influenza Preparedness & Response
Archived on August 30, 2026. Original response deadline: . Full description on SAM.gov.
Overview
- Response deadline
- 5:00 PM EDT
- Posted
- July 31, 2026
- Notice type
- Presolicitation
- Set-aside
- No Set aside used
- NAICS
- 541714: Research and Development in Biotechnology (except Nanobiotechnology)
- Agency
- Department of Health and Human ServicesOFFICE OF ASSISTANT SECRETARY FOR PREPAREDNESS AND RESPONSE
Notice details
- Office
- BARDA - ASPR / DAAPPO / BARDA DCMA
- Place of performance
- Washington, District of Columbia, 20024
- PSC
- AN12: R&D- MEDICAL: BIOMEDICAL (APPLIED RESEARCH/EXPLORATORY DEVELOPMENT)
- Last updated
- Oct 28, 2026
- First published
- Last updated on SAM.gov
Identifiers
- Solicitation number
- 75A50126R00001_RFP_PreSolNotice_NPIVS-2027
- Notice ID
- 7f2d0909120749a39c61c64ff933f1a6
Description
Description:
BARDA seeks Contractor(s) to support the continuation of the Vaccine MCMs for Pandemic Influenza Preparedness and Response Program. Contractors will furnish all the necessary services, qualified personnel, materials, supplies, equipment and facilities (U.S. facilities preferred) not otherwise provided by the USG as needed to provide MCMs, such as vaccines, antigens, and adjuvants, for pandemic preparedness and response or as required in response to a public health emergency; produce antigen and vaccines against influenza virus or other viruses with pandemic potential as required by BARDA; produce antigens, adjuvants, and/or vaccines to support USG efforts to further improve influenza vaccines (for which feasibility data is available); and support rapid regulatory decisions and manufacturing readiness by generating and submitting to FDA all relevant data (e.g., analytical, nonclinical, clinical, and/or chemistry, manufacturing, and controls (CMC)), including data generated during interpandemic periods.
Mandatory Qualification Requirements:
To be eligible for award, the Offeror must produce vaccines against influenza and influenza strains with pandemic potential; must demonstrate a successful experience in the manufacturing of influenza vaccine by:
- Holding a U.S. influenza vaccine license; or
- Have developed an influenza vaccine as evidenced by: a.Submission of a BLA for seasonal or pandemic influenza vaccine
Please see attachment to this presolicitation notice for further important information.
Award Overview
Contacts
Contracting Officer
Primary Contact
Documents
Files (1)
- Download
75A50126R00001 NPIVS RFP_PresolNotice.pdf
160 KBAdded in Presolicitation version 7Posted
Lifecycle
- 3Version 3Sources SoughtArchived
BARDA Vaccine Medical Countermeasures for Pandemic Influenza Preparedness & Response
- 7Version 7PresolicitationArchivedCurrent
Type changed from Sources Sought to Presolicitation
Presolicitation Notice - BARDA Vaccine Medical Countermeasures for Pandemic Influenza Preparedness & Response
- 5Version 5Solicitation
Type changed from Presolicitation to Solicitation
Request of Proposals (RFP) - BARDA Vaccine Medical Countermeasures for Pandemic Influenza Preparedness & Response
Similar Opportunities
Additional Details
Solicitation Number
75A50126R00001_RFP_PreSolNotice_NPIVS-2027
Archive Date
Aug 30, 2026
Office Address
WASHINGTON, DC, 20515